Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 15/100

Failure Rate

9.2%

26 terminated/withdrawn out of 282 trials

Success Rate

89.4%

+2.9% vs industry average

Late-Stage Pipeline

33%

93 trials in Phase 3/4

Results Transparency

55%

121 of 219 completed trials have results

Key Signals

17 recruiting121 with results21 terminated5 withdrawn

Enrollment Performance

Analytics

Phase 1

88(33.3%)

Phase 3

86(32.6%)

Phase 2

78(29.5%)

Phase 4

7(2.7%)

N/A

5(1.9%)

264Total

Phase 1(88)

Phase 3(86)

Phase 2(78)

Phase 4(7)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (282)

Showing 20 of 282 trials

NCT07570069Phase 1Not Yet Recruiting

Effects of Efavirenz on the Pharmacokinetics of Suzetrigine in Healthy Participants

Role: lead

NCT05791201Phase 1Active Not Recruiting

A Safety, Tolerability, and Efficacy Study of VX-264 in Participants With Type 1 Diabetes

Role: lead

NCT06794996Phase 2Active Not Recruiting

Inaxaplin in Participants With Proteinuric APOL1 Mediated Kidney Disease With or Without Comorbidities

Role: lead

NCT05444257Phase 3Active Not Recruiting

A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy

Role: lead

NCT07501702Phase 2Recruiting

A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis

Role: lead

NCT05844449Phase 3Enrolling By Invitation

Evaluation of Long-Term Safety and Efficacy of Vanzacaftor/Tezacaftor/Deutivacaftor in Cystic Fibrosis Participants 1 Year of Age and Older

Role: lead

NCT07463430Phase 4Enrolling By Invitation

Suzetrigine for Non-Mastectomy Breast Surgery

Role: collaborator

NCT06628908Phase 3Recruiting

Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy

Role: lead

NCT07231419Phase 3Recruiting

Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy

Role: lead

NCT07161037Phase 2Recruiting

Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)

Role: lead

NCT07204275Phase 2Recruiting

Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)

Role: lead

NCT06747572Active Not Recruiting

Polycystic Kidney Disease 1 (PKD1) Gene Variant Groups in Autosomal Dominant Polycystic Kidney Disease

Role: lead

NCT06619860Phase 2Recruiting

Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy

Role: lead

NCT07538570Phase 4Not Yet Recruiting

Evaluation of Pain Treatment After Total Knee Arthroplasty

Role: lead

NCT05312879Phase 2Recruiting

Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1-Mediated Proteinuric Kidney Disease

Role: lead

NCT06154447Phase 1Recruiting

Evaluation of VX-828 in Healthy Participants and in Participants With Cystic Fibrosis

Role: lead

NCT07349394Phase 1Completed

Effect of Vanzacaftor/Tezacaftor/Deutivacaftor (VNZ/TEZ/D-IVA) on the PK of Rosuvastatin in Healthy Participants

Role: lead

NCT07437105Phase 1Recruiting

Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants

Role: lead

NCT05422222Phase 3Recruiting

Evaluation of VX-121/Tezacaftor/Deutivacaftor in Cystic Fibrosis (CF) Participants 1 Through 11 Years of Age

Role: lead

NCT07074327Phase 1Completed

Effects of VX-407 on the Pharmacokinetics of Oral Contraceptives in Healthy Participants

Role: lead